A more in-depth analysis of TGFβ-treated SCC22A cells revealed—as expected for cancer cells undergoing EMT—reduced expression of epithelial marker zonula occludens-1 (ZO-1) paralleled by augmented protein expression of mesenchymal marker N-cadherin, EMT marker vimentin, and transcriptional EMT master regulator ZEB1 in control-treated but not La-depleted cancer cells upon TGFβ treatment (Figure 5 and Figure S3). The gene discussed is VIM; the disease is cancer.